These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 31229535)

  • 1. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling.
    Paudel YN; Angelopoulou E; Piperi C; Balasubramaniam VRMT; Othman I; Shaikh MF
    Eur J Pharmacol; 2019 Sep; 858():172487. PubMed ID: 31229535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-mobility group box-1 in sterile inflammation.
    Tsung A; Tohme S; Billiar TR
    J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs.
    Behl T; Sharma E; Sehgal A; Kaur I; Kumar A; Arora R; Pal G; Kakkar M; Kumar R; Bungau S
    Mol Biol Rep; 2021 Feb; 48(2):1869-1881. PubMed ID: 33479829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Inflammation Driven by HMGB1.
    Yang H; Wang H; Andersson U
    Front Immunol; 2020; 11():484. PubMed ID: 32265930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGB1 and RAGE in inflammation and cancer.
    Sims GP; Rowe DC; Rietdijk ST; Herbst R; Coyle AJ
    Annu Rev Immunol; 2010; 28():367-88. PubMed ID: 20192808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    van Beijnum JR; Buurman WA; Griffioen AW
    Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors.
    Rauvala H; Rouhiainen A
    Biochim Biophys Acta; 2010; 1799(1-2):164-70. PubMed ID: 19914413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: Therapeutic Targeting of HMGB1 in Stroke.
    Tian X; Liu C; Shu Z; Chen G
    Curr Drug Deliv; 2017 Sep; 14(6):785-790. PubMed ID: 27501713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High mobility group box-1 induces pro-inflammatory signaling in human nucleus pulposus cells via toll-like receptor 4-dependent pathway.
    Shah BS; Burt KG; Jacobsen T; Fernandes TD; Alipui DO; Weber KT; Levine M; Chavan SS; Yang H; Tracey KJ; Chahine NO
    J Orthop Res; 2019 Jan; 37(1):220-231. PubMed ID: 30273982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGB1 is a promising therapeutic target for asthma.
    Zhao Y; Li R
    Cytokine; 2023 May; 165():156171. PubMed ID: 36924610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of High-Mobility Group Box-1 in Liver Pathogenesis.
    Khambu B; Yan S; Huda N; Yin XM
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
    Musumeci D; Roviello GN; Montesarchio D
    Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGB1: An overview of its roles in the pathogenesis of liver disease.
    Ni YA; Chen H; Nie H; Zheng B; Gong Q
    J Leukoc Biol; 2021 Nov; 110(5):987-998. PubMed ID: 33784425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
    Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
    Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation.
    Andersson U; Tracey KJ; Yang H
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results.
    Paudel YN; Angelopoulou E; Piperi C; Othman I; Shaikh MF
    Pharmacol Res; 2020 Jun; 156():104792. PubMed ID: 32278047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Nguyen AH; Detty SQ; Agrawal DK
    Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of receptor for advanced glycation end products and high-mobility group box 1 in human dental pulp inflammation.
    Tancharoen S; Tengrungsun T; Suddhasthira T; Kikuchi K; Vechvongvan N; Tokuda M; Maruyama I
    Mediators Inflamm; 2014; 2014():754069. PubMed ID: 25114379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain.
    Agalave NM; Svensson CI
    Mol Med; 2015 Feb; 20(1):569-78. PubMed ID: 25222915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.